Correlations between glycolysis with clinical traits and immune function in bladder urothelial carcinoma

Che, Kai; Han, Wenkai; Li, Danxia; Cui, Shuxia; Zhang, Mingxin; Yang, Xiaokun; Niu, Haitao

doi:10.1042/bsr20203982

Cited by 8 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this study reveals for the first time the regulatory effect of cancer cell‐expressed IDO1 on glycolysis. Previous bioinformatic analyses have examined the IDO1–glycolysis link in tumor tissues, 49,50 yet they fell short of concretely defining the role of cancer cell‐expressed IDO1 in glycolysis. This gap in understanding is significant, considering that both immune and tumor cells can express IDO1.…”

Section: Discussionmentioning

confidence: 99%

Tryptophan deficiency induced by indoleamine 2,3‐dioxygenase 1 results in glucose transporter 1‐dependent promotion of aerobic glycolysis in pancreatic cancer

Liang,

Zhan,

Chen

et al. 2024

MedComm

View full text Add to dashboard Cite

Indoleamine 2,3‐dioxygenase 1 (IDO1), the key enzyme in the catabolism of the essential amino acid tryptophan (Trp) through kynurenine pathway, induces immune tolerance and is considered as a critical immune checkpoint, but its impacts as a metabolism enzyme on glucose and lipid metabolism are overlooked. We aim to clarify the potential role of IDO1 in aerobic glycolysis in pancreatic cancer (PC). Analysis of database revealed the positive correlation in PC between the expressions of IDO1 and genes encoding important glycolytic enzyme hexokinase 2 (HK2), pyruvate kinase (PK), lactate dehydrogenase A (LDHA) and glucose transporter 1 (GLUT1). It was found that IDO1 could modulate glycolysis and glucose uptake in PC cells, Trp deficiency caused by IDO1 overexpression enhanced glucose uptake by stimulating GLUT1 translocation to the plasma membrane of PC cells. Besides, Trp deficiency caused by IDO1 overexpression suppressed the apoptosis of PC cells via promoting glycolysis, which reveals the presence of IDO1–glycolysis–apoptosis axis in PC. IDO1 inhibitors could inhibit glycolysis, promote apoptosis, and exhibit robust therapeutic efficacy when combined with GLUT1 inhibitor in PC mice. Our study reveals the function of IDO1 in the glucose metabolism of PC and provides new insights into the therapeutic strategy for PC.

show abstract

Section: Discussionmentioning

confidence: 99%

Tryptophan deficiency induced by indoleamine 2,3‐dioxygenase 1 results in glucose transporter 1‐dependent promotion of aerobic glycolysis in pancreatic cancer

Liang,

Zhan,

Chen

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

“…Cancer cells with high glycolytic activity therefore have a strong ability to evade immune surveillance due to the impaired ability of immune cells to kill cancer cells. [114] However, extensive research is now being focused on ways to improve the antitumor effects of immune cells, such as by inhibiting the glycolysis of tumor cells.…”

Section: Exosomes As a Next-generation Drug Delivery Platformmentioning

confidence: 99%

Crosstalk between the tumor microenvironment and tumor cells through exosomes: Roles in tumor metabolism and progression

Shi,

Du,

Pan

et al. 2023

J Nutr Oncol

View full text Add to dashboard Cite

Tumor proliferation, metabolism, metastasis, and chemoresistance are intimately related to the tumor microenvironment (TME). The metabolic reprogramming of tumor cells is a hallmark of their adaptation to hypoxic and nutrient-deficient TMEs. Exosomes, a type of extracellular vesicle, have been found to regulate the crosstalk between tumor cells and the TME, affecting tumor metabolic reprogramming. In this review, we introduce the metabolic characteristics of tumor cells; describe the crosstalk between tumor cells and the TME in terms of glucose metabolism, lipid metabolism, and amino acid metabolism through exosomes; and provide an overview of the diagnostic and therapeutic potential of exosomes. A better understanding of tumor metabolism would provide a broader perspective about the mechanisms underlying tumor pathology and would facilitate the search for therapeutic targets and guide more individualized tumor treatment.

show abstract

“…GPI carries out the second step of catalytic glycolysis. In BC, GPI and other glycolytic enzymes are upregulated during cancer progression [ 20 ]. Overexpression of GPI has also been detected in other cancer types [ 21 ].…”

Section: Glycolysis Pathway In Ucmentioning

confidence: 99%

Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer

Yang

Chuang

Kuo

et al. 2021

IJMS

View full text Add to dashboard Cite

Urothelial cancer is a malignant tumor with metastatic ability and high mortality. Malignant tumors of the urinary system include upper tract urothelial cancer and bladder cancer. In addition to typical genetic alterations and epigenetic modifications, metabolism-related events also occur in urothelial cancer. This metabolic reprogramming includes aberrant expression levels of genes, metabolites, and associated networks and pathways. In this review, we summarize the dysfunctions of glycolytic enzymes in urothelial cancer and discuss the relevant phenotype and signal transduction. Moreover, we describe potential prognostic factors and risks to the survival of clinical cancer patients. More importantly, based on several available databases, we explore relationships between glycolytic enzymes and genetic changes or drug responses in urothelial cancer cells. Current advances in glycolysis-based inhibitors and their combinations are also discussed. Combining all of the evidence, we indicate their potential value for further research in basic science and clinical applications.

show abstract

Correlations between glycolysis with clinical traits and immune function in bladder urothelial carcinoma

Cited by 8 publications

References 43 publications

Tryptophan deficiency induced by indoleamine 2,3‐dioxygenase 1 results in glucose transporter 1‐dependent promotion of aerobic glycolysis in pancreatic cancer

Tryptophan deficiency induced by indoleamine 2,3‐dioxygenase 1 results in glucose transporter 1‐dependent promotion of aerobic glycolysis in pancreatic cancer

Crosstalk between the tumor microenvironment and tumor cells through exosomes: Roles in tumor metabolism and progression

Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer

Contact Info

Product

Resources

About